Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology and Blood Transfusion, Czech Republic
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
PedAL BCU, LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Manchester
M.D. Anderson Cancer Center
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Southern California
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ciusss de L'Est de l'Île de Montréal
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital, Basel, Switzerland
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Stanford University
Haukeland University Hospital
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Columbia University
M.D. Anderson Cancer Center
Heinrich-Heine University, Duesseldorf
Indiana University
University Hospital, Basel, Switzerland
M.D. Anderson Cancer Center
Indiana University
M.D. Anderson Cancer Center
University of Nebraska
University of Washington
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital with Nanjing Medical University
Wuerzburg University Hospital
Chinese PLA General Hospital
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center